These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 38637785

  • 1. Prevalence of overweight and obesity among adolescents living with HIV after dolutegravir - based antiretroviral therapy start in Kampala, Uganda.
    Nakatudde I, Katana E, Agnes Odongpiny EL, Nalugga EA, Castelnuovo B, Fowler MG, Musoke P.
    AIDS Res Ther; 2024 Apr 18; 21(1):23. PubMed ID: 38637785
    [Abstract] [Full Text] [Related]

  • 2. Body weight and blood pressure changes on dolutegravir-, efavirenz- or atazanavir-based antiretroviral therapy in Zimbabwe: a longitudinal study.
    Shamu T, Egger M, Mudzviti T, Chimbetete C, Manasa J, Anderegg N.
    J Int AIDS Soc; 2024 Feb 18; 27(2):e26216. PubMed ID: 38332525
    [Abstract] [Full Text] [Related]

  • 3. ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing.
    Moore CL, Turkova A, Mujuru H, Kekitiinwa A, Lugemwa A, Kityo CM, Barlow-Mosha LN, Cressey TR, Violari A, Variava E, Cotton MF, Archary M, Compagnucci A, Puthanakit T, Behuhuma O, Saϊdi Y, Hakim J, Amuge P, Atwine L, Musiime V, Burger DM, Shakeshaft C, Giaquinto C, Rojo P, Gibb DM, Ford D, ODYSSEY Trial Team.
    BMC Infect Dis; 2021 Jan 04; 21(1):5. PubMed ID: 33446115
    [Abstract] [Full Text] [Related]

  • 4. Assessment of weight gain in adult patients living with HIV receiving first-line dolutegravir-based or efavirenz-based ART regimens in routine care clinics in Tshwane district, South Africa: An observational study.
    Sawry S, Ayalew K, Maimela G, Briggs-Hagen M, van Wyk-Heath M, Mthethwa S, Shai S, Mngomezulu NN, Tlhowe L, Achere-Darko J, Bedford J, Martin CE, Fairlie L, Imrie J.
    HIV Med; 2024 Jul 04; 25(7):826-839. PubMed ID: 38520085
    [Abstract] [Full Text] [Related]

  • 5. Unlocking the potential: exploring the impact of dolutegravir treatment on body mass index improvement in underweight adults with HIV in Malawi.
    Maphosa T, Dunga S, Makonokaya L, Woelk G, Maida A, Wang A, Ahimbisibwe A, Chamanga RK, Zimba SB, Kayira D, Machekano R.
    BMC Public Health; 2024 May 16; 24(1):1321. PubMed ID: 38755632
    [Abstract] [Full Text] [Related]

  • 6. "It's only fatness, it doesn't kill": a qualitative study on perceptions of weight gain from use of dolutegravir-based regimens in women living with HIV in Uganda.
    Alhassan Y, Twimukye A, Malaba T, Myer L, Waitt C, Lamorde M, Colbers A, Reynolds H, Khoo S, Taegtmeyer M.
    BMC Womens Health; 2022 Jun 21; 22(1):246. PubMed ID: 35729541
    [Abstract] [Full Text] [Related]

  • 7. Patient experiences of switching from Efavirenz- to Dolutegravir-based antiretroviral therapy: a qualitative study in Uganda.
    Twimukye A, Laker M, Odongpiny EAL, Ajok F, Onen H, Kalule I, Kajubi P, Seden K, Owarwo N, Kiragga A, Armstrong-Hough M, Katahoire A, Mujugira A, Lamorde M, Castelnuovo B.
    BMC Infect Dis; 2021 Nov 13; 21(1):1154. PubMed ID: 34774018
    [Abstract] [Full Text] [Related]

  • 8. Barriers to viral load suppression among adolescents living with HIV on anti-retroviral therapy: a retrospective study in Tanga, Tanzania.
    Mushy SE, Mtisi E, Mkawe S, Mboggo E, Ndega J, Yahya-Malima KI, Kamugunya D, Kilimba ES, Mlay BS, Muya A, Ngalesoni F.
    AIDS Res Ther; 2024 May 22; 21(1):35. PubMed ID: 38778318
    [Abstract] [Full Text] [Related]

  • 9. Provider perspectives on the acceptability and tolerability of dolutegravir-based anti-retroviral therapy after national roll-out in Uganda: a qualitative study.
    Zakumumpa H, Kitutu FE, Ndagije HB, Diana NK, Ssanyu JN, Kiguba R.
    BMC Infect Dis; 2021 Dec 07; 21(1):1222. PubMed ID: 34876050
    [Abstract] [Full Text] [Related]

  • 10. Virological, weight, and drug resistance outcomes among patients initiating a dolutegravir-based first-line antiretroviral therapy regimen in Zimbabwe.
    Kouamou V, Washaya T, Mapangisana T, Ndhlovu CE, Manasa J.
    AIDS; 2024 Apr 01; 38(5):689-696. PubMed ID: 38227596
    [Abstract] [Full Text] [Related]

  • 11. Switch to dolutegravir is well tolerated in Thais with HIV infection.
    Goh OQ, Colby DJ, Pinyakorn S, Sacdalan C, Kroon E, Chan P, Chomchey N, Kanaprach R, Prueksakaew P, Suttichom D, Trichavaroj R, Spudich S, Robb ML, Phanuphak P, Phanuphak N, Ananworanich J, RV254/SEARCH 010 Study Group.
    J Int AIDS Soc; 2019 Jul 01; 22(7):e25324. PubMed ID: 31294931
    [Abstract] [Full Text] [Related]

  • 12. An observational cohort study to investigate the impact of dolutegravir in pregnancy and its obesogenic effects on the metabolic health of women living with HIV and their children: Study protocol.
    Abrams EJ, Jao J, Madlala HP, Zerbe A, Catalano P, Gerschenson M, Goedecke JH, Gomba Y, Josefson J, Kurland IJ, Legbedze J, McComsey GA, Matyesini S, Mukonda E, Robinson D, Myer L.
    PLoS One; 2024 Jul 01; 19(8):e0307296. PubMed ID: 39159183
    [Abstract] [Full Text] [Related]

  • 13. A Phase-IV Non-interventional Study to Assess Virological Effectiveness, Safety, and Tolerability of DTG-based Antiretroviral Therapy in HIV-1 Infected Indian Persons Living with HIV.
    Ashta KK, Arora S, Khanna R, Raman N, Anilkumar A, Mohan C.
    Curr HIV Res; 2024 Jul 01; 22(1):31-46. PubMed ID: 38284697
    [Abstract] [Full Text] [Related]

  • 14. High viral suppression rates among PLHIV on dolutegravir who had an initial episode of viral non-suppression in Uganda September 2020-July 2021.
    Namayanja GA, Da Silva JF, Elur B, Nasirumbi PM, Raizes E, Ssempiira J, Nazziwa E, Nabukenya M, Sewanyana I, Balaba J, Ntale J, Calnan J, Birabwa E, Akao J, Mwangi C, Naluguza M, Ahimbisibwe A, Katureebe C, Nabadda S, Nelson L, Dirlikov E.
    PLoS One; 2024 Jul 01; 19(6):e0305129. PubMed ID: 38923981
    [Abstract] [Full Text] [Related]

  • 15. The association between adherence to antiretroviral therapy and viral suppression under dolutegravir-based regimens: an observational cohort study from Uganda.
    Wagner Z, Wang Z, Stecher C, Karamagi Y, Odiit M, Haberer JE, Linnemayr S.
    J Int AIDS Soc; 2024 Aug 01; 27(8):e26350. PubMed ID: 39155425
    [Abstract] [Full Text] [Related]

  • 16. Prevalence of Emergent Dolutegravir Resistance Mutations in People Living with HIV: A Rapid Scoping Review.
    Chu C, Tao K, Kouamou V, Avalos A, Scott J, Grant PM, Rhee SY, McCluskey SM, Jordan MR, Morgan RL, Shafer RW.
    Viruses; 2024 Mar 04; 16(3):. PubMed ID: 38543764
    [Abstract] [Full Text] [Related]

  • 17. Effectiveness, Weight Changes, and Metabolic Outcomes on Switch to Generic Dolutegravir/Lamivudine Among People with HIV in Western India: An Observational Study.
    Pujari S, Gaikwad S, Panchawagh S, Chitalikar A, Joshi K, Rohekar C, Dabhade D, Bele V.
    AIDS Res Hum Retroviruses; 2024 Apr 04; 40(4):204-215. PubMed ID: 38063004
    [Abstract] [Full Text] [Related]

  • 18. Weight gain during the dolutegravir transition in the African Cohort Study.
    Esber AL, Chang D, Iroezindu M, Bahemana E, Kibuuka H, Owuoth J, Singoei V, Maswai J, Dear NF, Crowell TA, Polyak CS, Ake JA, AFRICOS Study Group.
    J Int AIDS Soc; 2022 Apr 04; 25(4):e25899. PubMed ID: 35419973
    [Abstract] [Full Text] [Related]

  • 19. Gestational weight gain and adverse birth outcomes in South African women with HIV on antiretroviral therapy and without HIV: a prospective cohort study.
    Madlala HP, Myer L, Jao J, Geffen H, Matjila M, Fisher A, Meyer D, Werner EF, Petro G, Cu-Uvin S, McGarvey ST, Bengtson AM.
    J Int AIDS Soc; 2024 Jun 04; 27(6):e26313. PubMed ID: 38926935
    [Abstract] [Full Text] [Related]

  • 20. Dolutegravir is not associated with weight gain in antiretroviral therapy experienced geriatric patients living with HIV.
    Guaraldi G, Calza S, Milic J, Calcagno A, Focà E, Rota M, Renzetti S, Celotti A, Siano M, Celesia BM, Piconi S, de Socio GV, Cattelan AM, Orofino G, Riva A, Nozza S, di Perri G.
    AIDS; 2021 May 01; 35(6):939-945. PubMed ID: 33635844
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.